Everest Medicines Ltd. reported its financial results for the first half of 2025, highlighting significant growth and operational efficiency. The company's total revenue reached RMB 446 million, marking a 48% year-over-year increase. This growth was supported by the strong market performance of core products NEFECON® and XERAVA®, as well as the introduction of VELSIPITY® to the Singapore market. The company reported a narrowing of non-IFRS loss by 31%, and the gross margin, excluding non-cash items, stood at 76.4%. Operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting enhanced operational efficiency. Research and development expenses for the period decreased to RMB 195.2 million from RMB 253.2 million, indicating strategic resource optimization. Distribution and selling expenses increased from RMB 200.4 million to RMB 314.7 million, driven by expanded commercial activities and the increased coverage of NEFECON® and XERAVA® across various regions. Everest Medicines also completed a successful share placement, raising net proceeds of HK$1.553 billion, which will be used to accelerate the development of its innovative pipeline and proprietary AI-enabled mRNA platform. The company maintains a solid cash balance of RMB 1.6 billion, providing a strong foundation for future growth.